MCID: DBT008
MIFTS: 44

Diabetic Angiopathy

Categories: Cardiovascular diseases

Aliases & Classifications for Diabetic Angiopathy

MalaCards integrated aliases for Diabetic Angiopathy:

Name: Diabetic Angiopathy 12 14
Diabetic Angiopathies 52 42 69
Diabetic Vascular Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11713
MeSH 42 D003925
NCIt 47 C35610
UMLS 69 C0011875

Summaries for Diabetic Angiopathy

MalaCards based summary : Diabetic Angiopathy, also known as diabetic angiopathies, is related to pneumoconiosis due to talc and unna-thost palmoplantar keratoderma. An important gene associated with Diabetic Angiopathy is IGFBP7 (Insulin Like Growth Factor Binding Protein 7), and among its related pathways/superpathways are TNF signaling pathway and Fluid shear stress and atherosclerosis. The drugs Glatiramer Acetate and Mannitol have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and bone, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and cardiovascular system

Wikipedia : 72 Diabetic angiopathy is a form of angiopathy associated with diabetes mellitus. While not exclusive, the... more...

Related Diseases for Diabetic Angiopathy

Diseases related to Diabetic Angiopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
id Related Disease Score Top Affiliating Genes
1 pneumoconiosis due to talc 10.5 BMP6 CCL2
2 unna-thost palmoplantar keratoderma 10.4 THBD VWF
3 retinitis pigmentosa 17 10.2 AGER INS
4 parotid disease 10.2 EDN1 VWF
5 intracranial primitive neuroectodermal tumor 10.2 CCL2 EDN1
6 female breast upper-outer quadrant cancer 10.1 CAT EDN1
7 psychologic dyspareunia 10.0 THBD VWF
8 urethral intrinsic sphincter deficiency 10.0 CCL2 SELE
9 intramuscular hemangioma 10.0 INS TNFRSF11B VWF
10 idiopathic juxtafoveal retinal telangiectasia 9.9 EDN1 INS
11 physical urticaria 9.9 BMP6 EDN1
12 neuropathy 9.9
13 de quervain disease 9.8 SELE THBD
14 elizabethkingia anophelis infection 9.8 EDN1 THBD VWF
15 chronic fatigue syndrome 9.8 EDN1 THBD VWF
16 endotheliitis 9.8
17 tonsil cancer 9.8 INS SELE
18 chronic graft versus host disease 9.8 SELE THBD
19 diamond-blackfan anemia 3 9.8 BMP6 CCL2 EDN1
20 acute proliferative glomerulonephritis 9.7 EDN1 THBD VWF
21 calcinosis 9.7 CCL2 EDN1 INS
22 craniopharyngioma 9.7 SELE THBD
23 vasculitis 9.6
24 vascular disease 9.6
25 hyperglycemia 9.6
26 pancreatitis 9.6
27 thyroiditis 9.6
28 cataract, autosomal dominant congenital 4 9.6 INS SELE VWF
29 stickler sydrome, type i, nonsyndromic ocular 9.6 SELE THBD
30 rheumatic myocarditis 9.6 BMP6 SELE
31 thumb stiff brachydactyly mental retardation 9.6 SELE THBD VWF
32 lymphadenitis 9.6 CAT EDN1
33 emphysema, congenital lobar 9.6 SELE THBD VWF
34 glossopharyngeal nerve disease 9.6 CCL2 SELE THBD
35 angina pectoris 9.6 SELE THBD VWF
36 malignant type ab thymoma 9.5 INS SELE VWF
37 dracunculiasis 9.4 INS SELE
38 lubani-al saleh-teebi syndrome 9.4 BMP6 EDN1 THBD VWF
39 chickenpox 9.3 CCL2 SELE THBD VWF
40 hypertension, essential 9.3 EDN1 INS THBD VWF
41 macular degeneration, age-related, 12 8.9 EDN1 INS SELE VWF
42 autoimmune hepatitis 8.7 AGER CCL2 EDN1 SELE THBD
43 myocardial infarction 8.7 AGER CCL2 EDN1 INS THBD VWF
44 peripheral artery disease 8.7 CCL2 EDN1 INS SELE VWF
45 malaria 8.6 CCL2 EDN1 SELE THBD VWF
46 myelophthisic anemia 8.5 CCL2 EDN1 INS SELE THBD
47 maturity-onset diabetes of the young 6 8.4 AGER CCL2 EDN1 INS SELE VWF
48 hepatic adenoma, somatic 8.1 AGER CAT EDN1 INS SELE THBD
49 pericarditis 7.1 AGER CAT CCL2 EDN1 INS SELE
50 neonatal diabetes mellitus 6.0 AGER BMP6 CAT CCL2 EDN1 IGFBP7

Graphical network of the top 20 diseases related to Diabetic Angiopathy:



Diseases related to Diabetic Angiopathy

Symptoms & Phenotypes for Diabetic Angiopathy

GenomeRNAi Phenotypes related to Diabetic Angiopathy according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 CAT INS PDGFRB

MGI Mouse Phenotypes related to Diabetic Angiopathy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 SELE THBD TNFRSF11B VWF AGER EDN1
2 cellular MP:0005384 9.91 AGER CAT IGFBP7 INS PDGFRB SELE
3 growth/size/body region MP:0005378 9.81 AGER BMP6 EDN1 IGFBP7 INS PDGFRB
4 immune system MP:0005387 9.56 AGER CCL2 INS PDGFRB SELE THBD
5 integument MP:0010771 9.1 AGER IGFBP7 INS PDGFRB SELE THBD

Drugs & Therapeutics for Diabetic Angiopathy

Drugs for Diabetic Angiopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 463)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
2
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
3
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
4
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
5
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
6
Aztreonam Approved Phase 4,Phase 2 78110-38-0 5362041 5742832
7
Clindamycin Approved, Vet_approved Phase 4,Phase 2 18323-44-9 29029
8
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
9
Linezolid Approved, Investigational Phase 4,Phase 2 165800-03-3 441401
10
Metronidazole Approved Phase 4,Phase 2 443-48-1 4173
11
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
12
Piperacillin Approved Phase 4,Phase 3,Phase 2 66258-76-2 43672
13
Tazobactam Approved Phase 4,Phase 3,Phase 2 89786-04-9 123630
14
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
15
Acarbose Approved, Investigational Phase 4,Early Phase 1 56180-94-0 441184
16
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
17
Fenofibrate Approved Phase 4,Phase 3 49562-28-9 3339
18
Ciprofloxacin Approved, Investigational Phase 4,Phase 2,Phase 1 85721-33-1 2764
19
Sulfamethoxazole Approved Phase 4,Phase 2 723-46-6 5329
20
Trimethoprim Approved, Vet_approved Phase 4,Phase 2 738-70-5 5578
21
Zinc Approved Phase 4,Phase 3,Phase 2,Early Phase 1 7440-66-6 32051 23994
22
Alginic acid Approved, Experimental Phase 4,Phase 1,Phase 2 9005-32-7
23
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
24
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
25
Petrolatum Approved Phase 4 8009-03-8
26
Dipivefrin Approved Phase 4 52365-63-6 3105
27
Cefepime Approved Phase 4,Phase 2 88040-23-7 5479537
28
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
29
Cefoxitin Approved Phase 4 35607-66-0 441199
30
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
31
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 564-25-0 54671203
32
Fusidic Acid Approved Phase 4 6990-06-3 3000226
33
Rifampin Approved Phase 4 13292-46-1 5458213 5381226
34
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
35
Sulbactam Approved Phase 4 68373-14-8
36
Insulin Glargine Approved Phase 4,Early Phase 1 160337-95-1
37
Temazepam Approved Phase 4,Phase 3,Phase 2,Phase 1 846-50-4 5391
38
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
39
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
40
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
41
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
42
Vancomycin Approved Phase 4,Phase 3,Phase 2 1404-90-6 441141 14969
43
Allopurinol Approved Phase 4 315-30-0 2094
44
Saxagliptin Approved Phase 4 361442-04-8 11243969
45
Empagliflozin Approved Phase 4 864070-44-0
46
Glimepiride Approved Phase 4 93479-97-1 3476
47
Bisoprolol Approved Phase 4 66722-44-9 2405
48
Captopril Approved Phase 4 62571-86-2 44093
49
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
50
Cilazapril Approved Phase 4 88768-40-5, 92077-78-6 56329 56330

Interventional clinical trials:

(show top 50) (show all 808)

id Name Status NCT ID Phase Drugs
1 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
2 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
3 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
4 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
5 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
6 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
7 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
8 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
9 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
10 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
11 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
12 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
13 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
14 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
15 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
16 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
17 Phase IV Study to Evaluate the Efficacy of AMNIOEXCEL in Diabetic Foot Ulcers Completed NCT02209051 Phase 4
18 Diabetic Foot Ulcer Study on Topical Interventions Completed NCT02577900 Phase 4
19 GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds Completed NCT02260609 Phase 4
20 Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot Completed NCT00224796 Phase 4
21 Santyl vs. Sharp Debridement of Diabetic Foot Wounds Completed NCT01056198 Phase 4 Santyl
22 DermACELL in Subjects With Chronic Wounds of the Lower Extremities Completed NCT01970163 Phase 4
23 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
24 Using Santyl on Diabetic Foot Ulcers Completed NCT01408277 Phase 4
25 Santyl Applications to Diabetic Foot Ulcers Completed NCT02111291 Phase 4
26 Use of Santyl in Diabetic Foot Ulcers Completed NCT02581488 Phase 4
27 Diabetic Foot Ulcer. Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water Completed NCT02097615 Phase 4
28 Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure Therapy™ in Diabetic Foot Ulcers Completed NCT00432965 Phase 4
29 Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers Completed NCT01596920 Phase 4
30 LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers Completed NCT01454401 Phase 4
31 Study of Oasis Ultra in Diabetic Foot Ulcers Completed NCT01835379 Phase 4
32 Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers Completed NCT00770939 Phase 4
33 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
34 A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers Completed NCT01143714 Phase 4 Santyl
35 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
36 TITLE: An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended Completed NCT01964521 Phase 4
37 Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers Completed NCT01143727 Phase 4 Santyl;Tegaderm Hydrogel
38 GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers Completed NCT02675855 Phase 4
39 Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers Completed NCT00235196 Phase 4
40 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema Completed NCT02366468 Phase 4 0.5 mg ranibizumab;0.5 mg ranibizumab
41 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4 Ranibizumab
42 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
43 Wound Edge Changes Following Treatment With Santyl Completed NCT01197898 Phase 4
44 OASIS Wound Matrix (Oasis) Mechanism of Action Completed NCT00570141 Phase 4
45 Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis Completed NCT02123628 Phase 4 duration of the antibiotic therapy
46 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
47 Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections Completed NCT00044746 Phase 4 Piperacillin/Tazobactam
48 Effect of the Adjunctive IVB Before PRP Completed NCT01504724 Phase 4 bevacizumab
49 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4 Ranibizumab
50 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab

Search NIH Clinical Center for Diabetic Angiopathy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: diabetic angiopathies

Genetic Tests for Diabetic Angiopathy

Anatomical Context for Diabetic Angiopathy

MalaCards organs/tissues related to Diabetic Angiopathy:

39
Eye, Skin, Bone, Endothelial, Bone Marrow, Testes, Retina

Publications for Diabetic Angiopathy

Articles related to Diabetic Angiopathy:

(show top 50) (show all 97)
id Title Authors Year
1
Redox Status of I^2GPI in Different Stages of Diabetic Angiopathy. ( 27818568 )
2016
2
[SMOKING AS A TRIGGER FACTOR IN THE DEVELOPMENT OF DIABETIC ANGIOPATHY OF LOWER EXTREMITIES IN MEN WITH METHYLENETETRAHYDROFOLATEREDUCTASE 677TT GENOTYPE]. ( 26596059 )
2015
3
Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. ( 22142668 )
2012
4
Is the advancement of diabetic angiopathy evaluated as ankle-brachial index directly associated with current glycaemic control? ( 23020057 )
2012
5
Diabetic angiopathy and angiogenic defects. ( 22853690 )
2012
6
Diabetic angiopathy. ( 22616224 )
2011
7
Peroxynitrite-induced nitration of cyclooxygenase-2 and inducible nitric oxide synthase promotes their binding in diabetic angiopathy. ( 20607198 )
2010
8
Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. ( 20098449 )
2010
9
Macrophage foam cell formation is augmented in serum from patients with diabetic angiopathy. ( 19939487 )
2010
10
Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. ( 20022399 )
2010
11
Diabetes in motion in the year of the child. Meeting Highlights - 33rd Annual ISPAD Meeting, September 26-29, 2007, Berlin, Germany - 5th Symposium on Diabetic Angiopathy in Children, September 30, 2007, Berlin, Germany. ( 18211630 )
2008
12
Oxidative stress-responsive transcription factor ATF3 potentially mediates diabetic angiopathy. ( 16428460 )
2006
13
Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. ( 15983321 )
2005
14
Diabetic angiopathy: new experimental and clinical aspects. ( 15918103 )
2005
15
The role of nitric oxide in the development of diabetic angiopathy. ( 15156413 )
2004
16
Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects. ( 15270792 )
2004
17
Aspirin resistance and diabetic angiopathy: back to the future. ( 15115664 )
2004
18
Pathophysiological mechanisms of diabetic angiopathy. ( 12623164 )
2003
19
Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging. ( 12623165 )
2003
20
[Growth hormone, insulin-like growth factor and insulin-like growth factor binding protein in young type I diabetes patients with the onset of diabetic angiopathy]. ( 12868196 )
2003
21
Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. ( 12429856 )
2002
22
Advanced glycation end products, their receptors and diabetic angiopathy. ( 11694852 )
2001
23
The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. ( 11674859 )
2001
24
Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. ( 11004428 )
2000
25
Growth hormone, IGF-I and diabetic angiopathy revisited. ( 10651747 )
2000
26
Advanced glycation end products in adolescents and young adults with diabetic angiopathy. ( 10955941 )
2000
27
Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. ( 10651746 )
2000
28
Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. ( 10809802 )
2000
29
Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. ( 10773002 )
2000
30
[Pathophysiologic aspects of diabetic angiopathy]. ( 10421989 )
1999
31
Controversies on the pathogenesis of diabetic angiopathy: which treatment for normotensive adolescents with microalbuminuria and type 1 diabetes? ( 9642665 )
1998
32
Quality Control of Diabetes Care and Chronic Complications in Young People after St. Vincent and Kos. Proceedings of the 4th International Workshop Diabetic Angiopathy in Children. Berlin, Germany, September 4-6, 1997. ( 9742011 )
1998
33
Molecular mechanisms of diabetic angiopathy--clues for innovative therapeutic interventions. ( 9676989 )
1998
34
Urinary free cortisol and its nyctohemeral variation in adolescents and young adults with IDDM: relation to endothelin 1 and indices of diabetic angiopathy. ( 11517960 )
1998
35
Von Willebrand factor in diabetic angiopathy. ( 9805643 )
1998
36
Endothelial dysfunction and pathogenesis of diabetic angiopathy. ( 9217873 )
1997
37
[Effects of xenotransplantation of pancreatic islet cells on immunological state of patients with diabetic angiopathies]. ( 9511343 )
1997
38
Diabetic angiopathy in children. ( 9455928 )
1997
39
The role of hyperglycemia and hyperinsulinemia in the pathogenesis of diabetic angiopathy. ( 8905209 )
1996
40
[The thromboxane-synthesis inhibitor Ibustrin in the treatment of diabetic angiopathies]. ( 9026936 )
1996
41
Prostacyclin-stimulating factor, novel protein, and diabetic angiopathy. ( 8674874 )
1996
42
Diabetic angiopathy: tracking down the culprits. ( 8807468 )
1996
43
Enhanced expression of platelet-derived growth factor-beta receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy. ( 8603774 )
1996
44
[The medical effect of magnetic-laser therapy in patients with diabetic angiopathies of the lower extremities]. ( 9138797 )
1996
45
[The results of a comparative study of the lipid peroxidation processes and of the malondialdehyde level of the blood cells in patients with diabetic angiopathies and during insulin therapy]. ( 7863440 )
1994
46
Endothelial dysfunction and diabetic angiopathy. ( 7867890 )
1994
47
[Activity of membrane-bound protein kinase C and ATPase in erythrocytes in diabetic angiopathy]. ( 8058653 )
1993
48
Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double blind trial versus placebo. ( 1644013 )
1992
49
Cell-cell interactions in diabetic angiopathy. ( 1396014 )
1992
50
[Acupuncture in the treatment of diabetic angiopathy of the lower extremities]. ( 1788185 )
1991

Variations for Diabetic Angiopathy

Expression for Diabetic Angiopathy

Search GEO for disease gene expression data for Diabetic Angiopathy.

Pathways for Diabetic Angiopathy

GO Terms for Diabetic Angiopathy

Cellular components related to Diabetic Angiopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 AGER BMP6 CAT CCL2 EDN1 IGFBP7
2 extracellular space GO:0005615 9.28 BMP6 CAT CCL2 EDN1 IGFBP7 INS
3 Weibel-Palade body GO:0033093 9.16 EDN1 VWF

Biological processes related to Diabetic Angiopathy according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.81 CAT CCL2 EDN1 TNFRSF11B
2 positive regulation of cell migration GO:0030335 9.8 EDN1 INS PDGFRB
3 aging GO:0007568 9.79 CAT CCL2 PDGFRB
4 skeletal system development GO:0001501 9.76 BMP6 EDN1 TNFRSF11B
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.74 AGER CAT INS
6 response to hypoxia GO:0001666 9.67 AGER CAT CCL2 EDN1
7 inflammatory response GO:0006954 9.65 AGER BMP6 CCL2 SELE TNFRSF11B
8 response to amino acid GO:0043200 9.63 CCL2 EDN1
9 response to wounding GO:0009611 9.63 AGER CCL2 VWF
10 response to tumor necrosis factor GO:0034612 9.61 CCL2 SELE
11 glucose transport GO:0015758 9.61 EDN1 INS
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.61 CAT INS PDGFRB
13 cellular response to fatty acid GO:0071398 9.6 CCL2 EDN1
14 positive regulation of collagen biosynthetic process GO:0032967 9.59 CCL2 PDGFRB
15 cellular response to platelet-derived growth factor stimulus GO:0036120 9.58 CCL2 PDGFRB
16 response to hyperoxia GO:0055093 9.56 CAT PDGFRB
17 positive regulation of calcium ion import GO:0090280 9.55 CCL2 PDGFRB
18 response to magnesium ion GO:0032026 9.54 BMP6 TNFRSF11B
19 negative regulation of blood coagulation GO:0030195 9.52 EDN1 THBD
20 response to retinoic acid GO:0032526 9.5 BMP6 IGFBP7 PDGFRB
21 leukocyte migration involved in inflammatory response GO:0002523 9.49 CCL2 SELE
22 maternal process involved in parturition GO:0060137 9.48 CCL2 EDN1
23 response to ozone GO:0010193 9.4 CAT EDN1
24 response to lipopolysaccharide GO:0032496 9.35 CCL2 EDN1 SELE THBD TNFRSF11B
25 positive regulation of mitotic nuclear division GO:0045840 9.33 EDN1 INS PDGFRB
26 response to activity GO:0014823 8.92 BMP6 CAT CCL2 EDN1

Molecular functions related to Diabetic Angiopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.26 CAT CCL2 EDN1 PDGFRB
2 cytokine activity GO:0005125 8.92 BMP6 CCL2 EDN1 TNFRSF11B

Sources for Diabetic Angiopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....